反应详情

To a solution of 2-[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepine (may be prepared as described in Description 35) (31 mg, 0.10 mmol) in dichloromethane (4 ml) was added acetone (24 mg, 0.42 mmol) and acetic acid (3 drops). The resulting mixture was stirred at room temperature, under argon, for 20 minutes. Sodium triacetoxyborohydride (89 mg, 0.42 mmol) was added and stirring continued overnight. The resulting crude mixture was diluted with methanol and then purified by SCX, eluting with methanol and then with 2M ammonia/methanol. The basic fractions were combined and solvent evaporated in vacuo. Crude product was purified further by column chromatography on silica gel, eluting with a mixture of 2M ammonia in methanol/dichloromethane (0-1%). Resulting crude product was purified further by column chromatography on silica gel, eluting with a mixture of 2M ammonia in methanol/dichloromethane (0-1%) to afford the title compound (E15). MS (ES+) m/e 338 [M+H]+.

1. stirringstirring continued overnight
2. custompurified by SCX
3. washeluting with methanol
4. customsolvent evaporated in vacuo
5. customCrude product was purified further by column chromatography on silica gel
6. washeluting with a mixture of 2M ammonia in methanol/dichloromethane (0-1%)
7. customResulting crude product
8. customwas purified further by column chromatography on silica gel
9. washeluting with a mixture of 2M ammonia in methanol/dichloromethane (0-1%)